Twist Bioscience Stock Price, News & Analysis

The DNA Data Storage Alliance, created by Twist Bioscience (TWST), Illumina (ILMN), and Western Digital (WDC), has published a white paper titled “Preserving our Digital Legacy: An Introduction to DNA Data Storage.” This document discusses DNA storage's potential to address the exponential growth of digital data, highlighting that humans generated over 400 ZB of data in 2020. The paper outlines DNA's unprecedented storage density, stability, and sustainability compared to existing technologies. The Alliance aims to develop standards for interoperability in DNA storage solutions as the technology evolves.

Twist Bioscience (Nasdaq: TWST) has commenced shipping synthetic RNA reference controls for the SARS-CoV-2 Kappa variant (B.1.617.1). The company is also developing controls for the Delta (B.1.617.2) and B.1.617.3 variants. This initiative comes as India faces a significant COVID-19 outbreak and a high number of unvaccinated individuals. CEO Emily M. Leproust highlighted the company's commitment to provide essential tools to combat the virus globally, including controls for detecting new strains. Twist aims to support health and sustainability through its sophisticated DNA synthesis platform.

Twist Bioscience Corporation (Nasdaq: TWST) has launched the Twist Library Preparation Enzymatic Fragmentation Kit 2.0, an all-in-one solution designed to enhance accuracy and efficiency in library construction for next-generation sequencing (NGS). This kit is particularly suitable for challenging applications, including liquid biopsy and somatic variant testing, and excels with samples of limited or degraded DNA, such as banked oncology samples. The launch emphasizes the importance of robust sample preparation technologies for generating high-quality sequencing data.

Twist Bioscience Corporation (NASDAQ: TWST) announced participation in two upcoming virtual investor conferences. CEO Emily Leproust and CFO Jim Thorburn will present at the Jefferies Virtual Healthcare Conference on June 1 at 11:30 AM ET and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 3:50 PM ET. Both presentations will be webcast live and available for replay for 30 days. Twist Bioscience is known for its innovative synthetic DNA technology, providing products across various sectors including healthcare and agriculture.

Twist Bioscience Corporation (NASDAQ: TWST) announces its support for the Engineering Biology Research Consortium (EBRC) and its Statement of Ethics in Engineering Biology Research. This initiative aims to advance ethical standards in engineering biology, which has significantly impacted fields like medicine and agriculture. The U.S. engineering biology sector contributed 5.1% to GDP in 2016. Twist emphasizes its commitment to biosecurity and ethical practices while encouraging collaboration among the scientific community to ensure responsible innovation.

Twist Bioscience (NASDAQ: TWST) reported strong financial results for Q2 FY2021, ending March 31, 2021. Total orders reached $41.7 million, up from $24.6 million year-over-year. Revenue grew to $31.2 million, compared to $19.3 million in the prior year. However, net loss for the quarter increased to $37.9 million, or $0.78 per share. The cash position stood robust at $555.7 million. The company is optimistic about growth in the second half of the fiscal year, particularly in its NGS and synthetic biology segments.

Twist Bioscience (Nasdaq: TWST) has announced a collaboration with Vivlion GmbH to develop CRISPR gRNA libraries for various applications in genome engineering and drug development. This partnership leverages Twist's high-quality synthetic DNA production capabilities and Vivlion's innovative 3Cs technology for creating uniform CRISPR libraries. The collaboration aims to enhance genomic research efficiency, enabling faster gene function analysis. The joint effort is expected to significantly impact R&D in functional genomics.

Twist Bioscience Corporation (NASDAQ: TWST) has announced plans to release its financial results for the fiscal 2021 second quarter on May 6, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results and provide a business update. The financial results will be accessible on the company's website under Investor Relations. Twist Bioscience is focused on pioneering DNA synthesis technology, catering to diverse industries including healthcare and agriculture.

Twist Bioscience Corporation (NASDAQ: TWST) has expanded its lease for the 'Factory of the Future' near Portland, Oregon, adding approximately 100,000 square feet to its existing 110,000-square-foot facility. This expansion supports the company's planned growth in synthetic DNA, including potential verticals like DNA data storage. CEO Emily M. Leproust emphasized the need for strategic space planning for future market opportunities. The financial commitment for the expansion begins in 2022, aiming to bolster Twist’s capabilities in synthetic biology and genomics.